Pretargeted Immuno-PET Enables Monoclonal Antibody Imaging Beyond the Blood–Brain Barrier
Open Access
- 6 November 2025
- journal article
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 22 (12) , 7600-7610
Abstract
Pretargeted PET imaging offers a powerful approach to improve nuclear imaging contrast and reduce systemic radiation exposure, yet its application in the brain has been limited by the blood-brain barrier (BBB). Here, we demonstrate, for the first time, successful pretargeted PET imaging of a brain target enabled by a bispecific antibody engineered for transferrin receptor-mediated BBB transcytosis. By combining this brain shuttle with a novel 18F-labeled tetrazine, we achieve specific, quantifiable detection of brain-localized Aβ aggregates, validated through PET imaging and histological analysis. This proof-of-concept establishes a versatile, noninvasive imaging platform with broad potential for assessing biologic drug candidates and CNS targets previously considered intractable.Keywords
Funding Information
- Kr?ftens Bek?mpelse
- Danmarks Frie Forskningsfond (8022-00187B)
- Novo Nordisk Fonden (NNF23OC0082288, NNF23SA0087869)
- HORIZON EUROPE Marie Sklodowska-Curie Actions (101110589)
- Horizon 2020 Framework Programme (668532, 670261)
- Innovationsfonden
- Lundbeck Foundation
- Research Foundation of Rigshospitalet
This publication has 39 references indexed in Scilit:
- Application of 89Zr-DFO*-immuno-PET to assess improved target engagement of a bispecific anti-amyloid-ß monoclonal antibodyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2023
- Lecanemab, Aducanumab, and Gantenerumab — Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer's DiseaseNeurotherapeutics, 2022
- Non-invasive Imaging of Antisense Oligonucleotides in the Brain via In Vivo Click ChemistryMolecular Imaging and Biology, 2022
- Quantification of amyloid PET for future clinical use: a state-of-the-art reviewEuropean Journal of Nuclear Medicine and Molecular Imaging, 2022
- In vivo imaging of alpha-synuclein with antibody-based PETNeuropharmacology, 2022
- On the consensus nomenclature rules for radiopharmaceutical chemistry – Reconsideration of radiochemical conversionNuclear Medicine and Biology, 2021
- Pretargeting in nuclear imaging and radionuclide therapy: Improving efficacy of theranostics and nanomedicinesBiomaterials, 2018
- Increased Brain Penetration and Potency of a Therapeutic Antibody Using a Monovalent Molecular ShuttleNeuron, 2014
- In Vivo Chemistry for Pretargeted Tumor Imaging in Live MiceAngewandte Chemie International Edition, 2010
- A novel approach for imaging brain–behavior relationships in mice reveals unexpected metabolic patterns during seizures in the absence of tissue plasminogen activatorNeuroImage, 2007